Fusion Antibodies (LSE:FAB) Tax Provision : £0.18 Mil (TTM As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Tax Provision?

Fusion Antibodies's tax provision for the six months ended in Sep. 2023 was £0.06 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2023 was £0.18 Mil.

Fusion Antibodies Tax Provision Historical Data

The historical data trend for Fusion Antibodies's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Tax Provision Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Tax Provision

Get a 7-Day Free Trial

0.24

0.38

-1.64

0.13

0.26

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Tax Provision	Get a 7-Day Free Trial											0.07	0.07	0.15	0.12	0.06

Fusion Antibodies Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.18 Mil.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022